May 15, 2019
Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) will face downward price adjustments on August 1 based on the results of its cost-effective assessment (CEA) conducted under the health ministry’s pilot program, albeit the reduction coming in at a paltry 1%. The...read more